8-KAcquisitions & DispositionsRegulation FDExhibits & Filings

Cencora, Inc. 8-K Report, Acquisition Completed (Nov 6, 2015)

Filed November 6, 2015For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) announced the successful completion of its acquisition of PharMEDium Healthcare Holdings, Inc. on November 6, 2015. This strategic move, previously disclosed in an October 7, 2015 filing, involved a cash purchase price of $2.575 billion, on a cash-free, debt-free basis, subject to customary adjustments. The acquisition signifies a significant expansion for Cencora, integrating PharMEDium, a company specializing in sterile pharmaceutical compounding, into its operations. This transaction is expected to enhance Cencora's service offerings and market position within the pharmaceutical supply chain. Investors should monitor the integration of PharMEDium and its impact on Cencora's future financial performance and growth trajectory.

Key Highlights

  • 1Cencora, Inc. has completed the acquisition of PharMEDium Healthcare Holdings, Inc.
  • 2The acquisition was finalized on November 6, 2015.
  • 3The purchase price for PharMEDium was $2.575 billion in cash.
  • 4The transaction was structured on a cash-free, debt-free basis, with potential for adjustments.
  • 5PharMEDium is now a wholly owned subsidiary of Cencora.
  • 6The completion of the acquisition was announced via a press release furnished as an exhibit.

Frequently Asked Questions

The main event reported is the completion of Cencora, Inc.'s acquisition of PharMEDium Healthcare Holdings, Inc.

Cencora paid $2.575 billion in cash for PharMEDium, on a cash-free, debt-free basis, subject to certain adjustments.

The acquisition officially closed on November 6, 2015.

PharMEDium Healthcare Holdings, Inc. is involved in sterile pharmaceutical compounding, making it a significant addition to Cencora's existing services.